Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma

Quanqiang Wang, Misheng Zhao, Tianyu Zhang, Bingxin Zhang, Ziwei Zheng, Zhili Lin, Shujuan Zhou, Zheng Dong, Zixing Chen, Sisi Zheng, Yu Zhang, Xuanru Lin, Rujiao Dong, Jingjing Chen, Honglan Qian, Xudong Hu, Yan Zhuang, Qianying Zhang, Songfu Jiang, Yongyong MaFrontiers in Pharmacology 2023 · DOI

Abstract

Background: Ferroptosis is a regulated form of cell death caused by excessive lipid peroxidation that significantly impacts tumor cell response. This study investigates the expression and prognostic value of ferroptosis-related genes (FRGs) in Multiple Myeloma (MM) to establish a risk-scoring model and nomogram for improved clinical applicability. Methods: Using transcriptomic data, the study identified prognostic FRGs via LASSO-Cox regression, established a risk model, and explored immune patterns and drug sensitivity. Findings were validated using qRT-PCR on MM cell lines and patient samples. Results: A ferroptosis-derived risk model accurately predicted MM prognosis, serving as an independent prognostic factor. High-risk scores correlated with poor survival, specific immune checkpoint gene expressions, and medication sensitivity. Conclusion: The study demonstrates a strong association between FRGs and MM, providing a novel prognostic model and highlighting ferroptosis as a potential therapeutic target.

Introduction: The Challenge of Multiple Myeloma

Multiple Myeloma (MM) is a hematologic malignancy characterized by the aberrant proliferation of plasma cells within the bone marrow. Despite significant therapeutic progress, the disease remains largely incurable for many, with a median 5-year survival rate that highlights the need for more precise prognostic tools. Currently, clinicians rely on the Revised International Staging System (R-ISS), but this system often lacks the granularity required for truly personalized treatment strategies.

Recent oncological research has turned its focus toward ferroptosis, a unique, iron-dependent form of regulated cell death. Because cancer cells frequently exhibit altered iron metabolism to support rapid growth, ferroptosis represents a potential "Achilles' heel" for tumors. This study sought to bridge the gap in our understanding of how ferroptosis-related genes (FRGs) influence MM progression and patient outcomes.

Methods and Model Development

The researchers utilized a multi-cohort approach, drawing transcriptomic data from the Gene Expression Omnibus (GEO), specifically datasets GSE136337 (training), GSE24080, and GSE4204 (validation). From an initial pool of 252 FRGs identified in the FerrDb database, univariate Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression were employed to distill a robust prognostic signature.

LASSO regression cross-validation was utilized to determine the optimal penalty parameter (lambda), ensuring the prognostic model's accuracy and minimizing overfitting.

Beyond bioinformatics, the team validated their findings experimentally. They performed quantitative real-time PCR (qRT-PCR) on four MM cell lines and bone marrow samples from 31 patients to confirm the expression levels of the identified marker genes.

Key Insights: The 5-Gene Signature

The final prognostic model centers on five specific genes: YY1AP1, AURKA, CDKN1A, RRM2, and STEAP3. These genes collectively form a "ferroptosis risk score" that serves as a powerful indicator of disease trajectory.

LASSO coefficient profiles of the five ferroptosis-related genes (*YY1AP1, AURKA, STEAP3, RRM2, CDKN1A*) that comprise the prognostic risk model.
  • Risk Factors: AURKA and RRM2 were found to be significantly overexpressed in MM patients compared to healthy controls, suggesting they actively promote tumor progression.
  • Protective Factors: Conversely, CDKN1A was identified as a protective gene, typically downregulated in more aggressive disease states.
  • Validation: The qRT-PCR results mirrored these findings, showing significant upregulation of the risk-associated genes in patient samples, thereby grounding the computational model in biological reality.

Results: Survival Prediction and Clinical Utility

The clinical implications of the ferroptosis risk score are substantial. Patients in the high-risk group faced significantly worse overall survival across all tested datasets. In the primary training cohort, the Hazard Ratio (HR) for the risk score was 2.896, indicating that high-risk patients were nearly three times more likely to experience poor outcomes.

The model's predictive power was further evidenced by its Area Under the Curve (AUC) of 0.70 for 5-year survival, which outperformed traditional clinical factors like age, albumin levels, and the R-ISS stage alone (AUC 0.604). To make these findings actionable for clinicians, the researchers integrated the risk score into a nomogram, a graphical tool that allows for the calculation of individual survival probabilities.

Immune Landscape and Therapeutic Implications

The study also explored the relationship between ferroptosis and the tumor microenvironment. High-risk patients exhibited higher levels of immune cell infiltration, specifically M0 macrophages and activated CD4 memory T cells. While an increase in immune cells might seem beneficial, the data suggests these tumors may be characterized by "immune exhaustion," potentially making them better candidates for specific checkpoint inhibitor therapies.

Furthermore, drug sensitivity analysis revealed that high-risk patients might respond more favorably to certain treatments, including ATRA (All-trans retinoic acid), cisplatin, and imatinib. This suggests that the ferroptosis risk score could eventually serve as a biomarker for selecting the most effective chemotherapy or immunotherapy for a given patient.

Conclusion and Future Directions

This comprehensive analysis underscores that ferroptosis is a critical factor in Multiple Myeloma prognosis. By developing a validated 5-gene risk model, the authors have provided a new lens through which to view MM progression and treatment response. While prospective clinical trials are necessary to bring this genetic screening into routine bedside care, the study marks a significant step toward more personalized and effective management of Multiple Myeloma.

Summary updated

Abstract

<b>Background:</b> One particular type of cellular death that is known as ferroptosis is caused by the excessive lipid peroxidation. It is a regulated form of cell death that can affect the response of the tumor cells. Currently, it is not known if the presence of this condition can affect the prognosis of patients with multiple myeloma (MM). <b>Methods:</b> In this study, we studied the expression differences and prognostic value of ferroptosis-related genes (FRGs) in MM, and established a ferroptosis risk scoring model. In order to improve the prediction accuracy and clinical applicability, a nomogram was also established. Through gene enrichment analysis, pathways closely related to high-risk groups were identified. We then explored the differences in risk stratification in drug sensitivity and immune patterns, and evaluated their value in prognostic prediction and treatment response. Lastly, we gathered MM cell lines and samples from patients to confirm the expression of marker FRGs using quantitative real-time PCR (qRT-PCR). <b>Results:</b> The ability to predict the survival of MM patients is a challenging issue. Through the use of a risk model derived from ferroptosis, we were able to develop a more accurate prediction of the disease's prognosis. They were then validated by a statistical analysis, which showed that the model is an independent factor in the prognosis of MM. Patients of high ferroptosis risk scores had a much worse chance of survival than those in the low-risk groups. The calibration and power of the nomogram were also strong. We noted that the link between the ferroptosis risk score and the clinical treatment was suggested by the FRG's significant correlation with the immune checkpoint genes and the medication sensitivity. We validated the predictive model using qRT-PCR. <b>Conclusion:</b> We demonstrated the association between FRGs and MM, and developed a new risk model for prognosis in MM patients. Our study sheds light on the potential clinical relevance of ferroptosis in MM and highlights its potential as a therapeutic target for patients with this disease.
BibTeX
@inproceedings{wang2023comprehensive,
  author = {Quanqiang Wang and Misheng Zhao and Tianyu Zhang and Bingxin Zhang and Ziwei Zheng and Zhili Lin and Shujuan Zhou and Zheng Dong and Zixing Chen and Sisi Zheng and Yu Zhang and Xuanru Lin and Rujiao Dong and Jingjing Chen and Honglan Qian and Xudong Hu and Yan Zhuang and Qianying Zhang and Songfu Jiang and Yongyong Ma},
  title = {{Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1203125},
}
Figure